RSV vaccine competition heats up as Pfizer’s shot for older adults gets FDA approval By: MarketWatch June 01, 2023 at 11:46 AM EDT Global market for RSV vaccine could reach $17 billion by 2033, analysts say. Read More >> Related Stocks: Astrazeneca Plc ADR Gsk Plc ADR Moderna Inc Pfizer Sanofi-Aventis S.A. ADR
